Dyne Therapeutics, Inc.

NASDAQ:DYN

Biotechnology

Healthcare
$15.87 +1.97%

+$0.38 today

Market cap
$2.97B
Beta
1.08
P/E (TTM)
-7.2
EPS (TTM)
-$2.74
52W Low $8.06High $25.00

Volume 2.93M

Average 1.71M

DYN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Dyne Therapeutics, Inc.NASDAQ: DYN

Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026

Cash & equivalents rises 39.4% from a year ago

Cash & equivalents stood at $676.11M at the end of Q2 FY2026, up 39.4% from a year earlier and down 10.2% from the prior quarter. Over 3 fiscal years it compounded at +73.1% a year.

Context

  • Cash & equivalents amounted to 68.0% of total assets at the end of Q2 FY2026, up 1.5 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +39.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$676.11M-10.2% QoQ
Last fiscal yearDec 2025
$893.37M+105.2% YoY
Year agoJun 2025
$485.04M+39.4% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+39.4%——
1 year+105.2%——
3-year CAGR+73.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
893.37M USD
Year-over-year change
+105.2%
4-year CAGR
+45.2%

Cash & Equivalents vs competitors

How DYN compares with its peers on the latest reported figures

  • DYN's Jun 2026 cash & equivalents of $676.11M is the 2nd highest of the 11 companies compared; the peer median is $237.11M.
  • Its year-over-year change of +39.4% is the 6th highest of 11, against a peer median of +27.0%.
  • Cash & equivalents amounts to 68.0% of total assets for DYN, versus a peer median of 32.3%.
DYN Competitors Peer median
Cash & Equivalents for DYN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PTCTPTC Therapeutics, Inc.Jun 2026$1.05B +3.2%+52.1%32.3%
DYNDyne Therapeutics, Inc.Jun 2026$676.11M +39.4%+73.1%68.0%
WVEWave Life Sciences Ltd.Mar 2026$544.59M +124.0%+89.5%93.3%
SRPTSarepta Therapeutics, Inc.Mar 2026$464.45M +92.8%-6.1%14.6%
SLDBSolid Biosciences Inc.Mar 2026$297.74M +41.4%-27.2%70.4%
IONSIonis Pharmaceuticals, Inc.Sep 2026$296.3M -12.4%+10.4%10.2%
LRMRLarimar Therapeutics, Inc.Mar 2026$177.91M +742.2%+47.1%85.3%
STOKStoke Therapeutics, Inc.Mar 2026$155.66M -43.4%-9.5%35.1%
CAPRCapricor Therapeutics, Inc.Mar 2026$105.42M +266.1%+210.6%32.3%
TRDAEntrada Therapeutics, Inc.Mar 2026$76.44M +12.7%+26.0%22.8%
PEPGPepGen Inc.Mar 2026$42.15M -3.4%-30.7%27.0%
Peer median (excluding DYN) $237.11M+27.0%+18.2%32.3%

Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents200.83M172.15M121.63M435.45M893.37M
Short-term Investments175.75M83.87M1.47M206.82M217.19M
Net Receivables00000
Inventory00000
Other Current Assets383K9.58M6.28M17.01M16.03M
Total Current Assets382.39M265.59M129.38M659.28M1.13B
Property, Plant & Equipment (Net)40.96M38.41M33.39M30.01M44.77M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets2.31M2.32M2.32M1.94M15.6M
Total Non-current Assets43.27M40.73M35.71M31.96M60.37M
Total Assets425.66M306.33M165.08M691.23M1.19B
Account Payables4.03M5.26M22.94M6.56M8.08M
Short-term Debt0004.85M5M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00017.75M37.55M
Total Current Liabilities28.72M28.09M51.1M42.26M50.63M
Long-term Debt000015.28M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0000148.92M
Total Non-current Liabilities28.74M25.87M22.7M19.14M164.2M
Total Liabilities57.47M53.96M73.79M61.4M214.83M
Common Stock6K6K6K10K16K
Retained Earnings(228.47M)(396.57M)(632.51M)(949.93M)(1.4B)
Accumulated OCI(269K)(571K)06K475K
Other Stockholders Equity00000
Minority Interest00000
Total Equity368.2M252.36M91.29M629.84M972.13M
Total Debt32.64M30.48M27.42M23.99M20.28M
Net Debt(168.19M)(141.66M)(94.21M)(411.46M)(873.09M)

Dyne Therapeutics, Inc.

NASDAQ:DYN

Intrinsic Alpha fair value

Locked

Current Price

$15.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.